Peregrine Ventures today realized the USD 500 million exit from CartiHeal (USD 350 million down payment plus an additional USD 150 million milestone). This exit follows the portfolio company’s Food and Drug Administration (FDA) approval of the Agili-C™ implant for the treatment of cartilage and osteochondral defects. Having achieved this milestone, the medical device company’s…
eTurboNews greinar eru eingöngu fyrir áskrifendur. Áskrift er FRJÁLS.
Áskrifendur skrá sig hér Smelltu hér til að gerast áskrifandi ÓKEYPIS
Áskrifendur skrá sig hér Smelltu hér til að gerast áskrifandi ÓKEYPIS
HVAÐ Á AÐ TAKA ÚR ÞESSARI GREIN:
- This exit follows the portfolio company’s Food and Drug Administration (FDA) approval of the Agili-C™ implant for the treatment of cartilage and osteochondral defects.
- Having achieved this milestone, the medical device company’s….
- Áskrift er ÓKEYPIS.
